AR099971A1 - UNIT DOSE FORM THAT INCLUDES EMTRICITABINE, TENOFOVIR, DARUNAVIR AND RITONAVIR AND A MONOLITICAL TABLET THAT INCLUDES DARUNAVIR AND RITONAVIR - Google Patents
UNIT DOSE FORM THAT INCLUDES EMTRICITABINE, TENOFOVIR, DARUNAVIR AND RITONAVIR AND A MONOLITICAL TABLET THAT INCLUDES DARUNAVIR AND RITONAVIRInfo
- Publication number
- AR099971A1 AR099971A1 ARP150101041A ARP150101041A AR099971A1 AR 099971 A1 AR099971 A1 AR 099971A1 AR P150101041 A ARP150101041 A AR P150101041A AR P150101041 A ARP150101041 A AR P150101041A AR 099971 A1 AR099971 A1 AR 099971A1
- Authority
- AR
- Argentina
- Prior art keywords
- ritonavir
- darunavir
- tenofovir
- emtricitabine
- granulate
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Forma de dosificación oral que comprende Emtricitabina, Tenofovir, Darunavir y Ritonavir y un comprimido monolítico que comprende Darunavir y Ritonavir y su uso para tratar infección por HIV. Reivindicación 23: Una formulación farmacéutica de acuerdo con cualquiera de las reivindicaciones precedentes caracterizada porque la forma de dosificación unitaria comprende: (a) aproximadamente 300 mg de tenofovir disoproxil fumarato, (b) aproximadamente 200 mg de emtricitabina, (c) aproximadamente 800 mg de darunavir y (d) menor o igual a aproximadamente 70 mg de ritonavir. Reivindicación 26: Una formulación farmacéutica de acuerdo con la reivindicación 25 caracterizada porque la capa simple comprende: (a) una mezcla de: (i) un granulado de darunavir con ritonavir extragranular o un granulado de darunavir con ritonavir intragranular, (es decir un granulado de darunavir-ritonavir), (ii) gránulos de emtricitabina, y (iii) gránulos de tenofovir (preferentemente tenofovir disoproxilo, y más preferentemente tenofovir disoproxil fumarato), (b) una mezcla de (i) un granulado de darunavir con ritonavir extragranular o un granulado de darunavir con ritonavir intragranular, (es decir un granulado de darunavir ritonavir), con (ii) gránulos que comprenden emtricitabina y tenofovir; o (c) una mezcla de: (i) un granulado de darunavir y (ii) gránulos que comprenden emtricitabina, tenofovir y ritonavir.Oral dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir and a monolithic tablet comprising Darunavir and Ritonavir and its use to treat HIV infection. Claim 23: A pharmaceutical formulation according to any of the preceding claims characterized in that the unit dosage form comprises: (a) approximately 300 mg of tenofovir disoproxil fumarate, (b) approximately 200 mg of emtricitabine, (c) approximately 800 mg of darunavir and (d) less than or equal to approximately 70 mg ritonavir. Claim 26: A pharmaceutical formulation according to claim 25 characterized in that the single layer comprises: (a) a mixture of: (i) a granulate of darunavir with extragranular ritonavir or a granulate of darunavir with intragranular ritonavir, (i.e. a granulate of darunavir-ritonavir), (ii) granules of emtricitabine, and (iii) granules of tenofovir (preferably tenofovir disoproxil, and more preferably tenofovir disoproxil fumarate), (b) a mixture of (i) a granulate of darunavir with extragranular ritonavir or a granulate of darunavir with intragranular ritonavir, (ie a granulate of darunavir ritonavir), with (ii) granules comprising emtricitabine and tenofovir; or (c) a mixture of: (i) a darunavir granulate and (ii) granules comprising emtricitabine, tenofovir and ritonavir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461976917P | 2014-04-08 | 2014-04-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR099971A1 true AR099971A1 (en) | 2016-08-31 |
Family
ID=58699992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150101041A AR099971A1 (en) | 2014-04-08 | 2015-04-07 | UNIT DOSE FORM THAT INCLUDES EMTRICITABINE, TENOFOVIR, DARUNAVIR AND RITONAVIR AND A MONOLITICAL TABLET THAT INCLUDES DARUNAVIR AND RITONAVIR |
Country Status (1)
Country | Link |
---|---|
AR (1) | AR099971A1 (en) |
-
2015
- 2015-04-07 AR ARP150101041A patent/AR099971A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP17084331A (en) | PHARMACEUTICAL FORMULATIONS | |
CY1124052T1 (en) | ORALLY DISPERSIBLE TABLET CONTAINING ESTETROL | |
EA201792591A1 (en) | PHARMACEUTICAL PREPARATIONS | |
ECSP16084317A (en) | PHARMACEUTICAL FORMULATIONS, PREPARATION PROCESSES AND METHODS OF USE | |
IL280083A (en) | Pharmaceutical dosage form which can be administered orally and has modified release | |
WO2015028875A3 (en) | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir | |
ECSP16086232A (en) | (R) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE | |
PE20160245A1 (en) | STABLE ANTI-TUBERCULOSIS PHARMACEUTICAL COMPOSITION IN A FORM OF A DISPERSABLE TABLET INCLUDING ISONIAZID GRANULES AND RIFAPENTINE GRANULES AND THEIR PREPARATION PROCESS | |
AR110374A1 (en) | DOSED FORMS OF MODIFIED GASTRORETENTIVE RELEASE FOR OPROZOMIB AND PROCESS FOR MANUFACTURING | |
ECSP16005208A (en) | STABLE ANTI-TUBERCULOSIS PHARMACEUTICAL COMPOSITION IN A FORM OF A COATED TABLET INCLUDING ISONIAZID GRANULES AND RIFAPENTINE GRANULES AND THEIR PREPARATION PROCESS | |
AR099971A1 (en) | UNIT DOSE FORM THAT INCLUDES EMTRICITABINE, TENOFOVIR, DARUNAVIR AND RITONAVIR AND A MONOLITICAL TABLET THAT INCLUDES DARUNAVIR AND RITONAVIR | |
MX2017013643A (en) | Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix. | |
CO2018010142A2 (en) | Mesalazine solid formula preparation process | |
CY1120749T1 (en) | PHARMACEUTICAL DOSAGE FORMS | |
UY37413A (en) | OPROZOMIB IMMEDIATE RELEASE FORMULATIONS | |
PH12020550456A1 (en) | Alcohol-resistant oral pharmaceutical compositions of lorazepam | |
CL2018002337A1 (en) | Pharmaceutical composition to prevent and treat sleep disorders | |
UA97982U (en) | DRESSING MEDICINE FOR TABLETS | |
CR20170601A (en) | PHARMACEUTICAL FORMULATIONS THAT INCLUDE TENOFOVIR AND EMTRICITABINA | |
TR201722102A2 (en) | A Pharmaceutical Product Containing Levodropropizine | |
UA120295U (en) | ANTI-THROMBOCITARY ACTION MEDICINAL PRODUCT | |
CL2015003409A1 (en) | Synergistic pharmaceutical composition of two analgesics with different pharmacokinetic profile | |
BR112018072583A2 (en) | stable tablet tablet pharmaceutical composition | |
UA109242U (en) | STABLE PHARMACEUTICAL COMPOSITION CONTAINING PROTEASOM INHIBITOR | |
CL2015003683A1 (en) | Amorphous oral pharmaceutical formulation comprising the use of the formulation in the preparation of a medicament useful in the treatment and / or prophylaxis of diseases associated with the herpesviridae group, preferably associated with cytomegalovirus cmv amorphous letermovir preparation process. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |